NO318575B1 - Stabile sammensetninger som omfatter levosimendan og alginsyre - Google Patents
Stabile sammensetninger som omfatter levosimendan og alginsyre Download PDFInfo
- Publication number
- NO318575B1 NO318575B1 NO20005312A NO20005312A NO318575B1 NO 318575 B1 NO318575 B1 NO 318575B1 NO 20005312 A NO20005312 A NO 20005312A NO 20005312 A NO20005312 A NO 20005312A NO 318575 B1 NO318575 B1 NO 318575B1
- Authority
- NO
- Norway
- Prior art keywords
- levosimendan
- composition
- alginic acid
- stated
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title claims abstract description 27
- 229960000692 levosimendan Drugs 0.000 title claims abstract description 27
- 239000000783 alginic acid Substances 0.000 title claims abstract description 13
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 13
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 13
- 229960001126 alginic acid Drugs 0.000 title claims abstract description 13
- 150000004781 alginic acids Chemical class 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 abstract description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 14
- 239000000654 additive Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920003093 Methocel™ K100 LV Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 1
- -1 Avicel PHI01 Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Jellies, Jams, And Syrups (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI980902A FI980902A (fi) | 1998-04-23 | 1998-04-23 | Levosimendaanin stabiileja koostumuksia |
PCT/FI1999/000331 WO1999055337A1 (en) | 1998-04-23 | 1999-04-23 | Stabile compositions comprising levosimendan and alginic acid |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20005312D0 NO20005312D0 (no) | 2000-10-20 |
NO20005312L NO20005312L (no) | 2000-11-21 |
NO318575B1 true NO318575B1 (no) | 2005-04-11 |
Family
ID=8551576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005312A NO318575B1 (no) | 1998-04-23 | 2000-10-20 | Stabile sammensetninger som omfatter levosimendan og alginsyre |
Country Status (33)
Country | Link |
---|---|
US (1) | US6531458B1 (ja) |
EP (1) | EP1079834B1 (ja) |
JP (1) | JP4475809B2 (ja) |
KR (1) | KR100590622B1 (ja) |
CN (1) | CN1165309C (ja) |
AT (1) | ATE231395T1 (ja) |
AU (1) | AU756338B2 (ja) |
BG (1) | BG64766B1 (ja) |
BR (1) | BR9909867A (ja) |
CA (1) | CA2329232C (ja) |
CZ (1) | CZ290911B6 (ja) |
DE (1) | DE69905034T2 (ja) |
DK (1) | DK1079834T3 (ja) |
EA (1) | EA002428B1 (ja) |
EE (1) | EE04143B1 (ja) |
ES (1) | ES2191426T3 (ja) |
FI (1) | FI980902A (ja) |
GE (1) | GEP20032942B (ja) |
HK (1) | HK1031998A1 (ja) |
HR (1) | HRP20000703B1 (ja) |
HU (1) | HUP0105446A3 (ja) |
ID (1) | ID26650A (ja) |
IL (2) | IL138950A0 (ja) |
MX (1) | MXPA00010368A (ja) |
NO (1) | NO318575B1 (ja) |
NZ (1) | NZ507455A (ja) |
PL (1) | PL192274B1 (ja) |
PT (1) | PT1079834E (ja) |
RS (1) | RS49955B (ja) |
SK (1) | SK284600B6 (ja) |
TR (1) | TR200003101T2 (ja) |
WO (1) | WO1999055337A1 (ja) |
ZA (1) | ZA200005630B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI980901A (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
WO2002064120A1 (fr) * | 2001-02-13 | 2002-08-22 | Taisho Pharmaceutical Co., Ltd. | Preparations de gel a usage interne |
EP1858518A1 (en) * | 2005-03-14 | 2007-11-28 | Orion Corporation | A combination treatment for enhancing diuresis |
EP3370693B1 (en) * | 2015-11-06 | 2020-01-08 | Carinopharm GmbH | Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate |
EP4076398A4 (en) | 2019-12-16 | 2024-01-03 | Tenax Therapeutics, Inc. | LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1509866A (en) | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
PT76448B (en) * | 1982-04-05 | 1986-03-20 | Merck Sharp & Dohme | Process for preparing stabilization of unstable drugs or food supplements containing antibiotics mainly ephrotomycin |
EP0123291A2 (en) | 1983-04-20 | 1984-10-31 | Kyowa Hakko Kogyo Co., Ltd. | Method for stabilizing interferon |
US4906630A (en) * | 1985-11-22 | 1990-03-06 | Rorer Pharmaceutical Corporation | Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds |
US4716042A (en) | 1986-06-16 | 1987-12-29 | American Home Products Corporation | Stabilized coated aspirin tablets |
GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
FI973804A (fi) * | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
-
1998
- 1998-04-23 FI FI980902A patent/FI980902A/fi unknown
-
1999
- 1999-04-23 CA CA002329232A patent/CA2329232C/en not_active Expired - Fee Related
- 1999-04-23 ES ES99916943T patent/ES2191426T3/es not_active Expired - Lifetime
- 1999-04-23 GE GEAP19995638A patent/GEP20032942B/en unknown
- 1999-04-23 DK DK99916943T patent/DK1079834T3/da active
- 1999-04-23 HU HU0105446A patent/HUP0105446A3/hu unknown
- 1999-04-23 AU AU35248/99A patent/AU756338B2/en not_active Ceased
- 1999-04-23 AT AT99916943T patent/ATE231395T1/de not_active IP Right Cessation
- 1999-04-23 DE DE69905034T patent/DE69905034T2/de not_active Expired - Lifetime
- 1999-04-23 MX MXPA00010368A patent/MXPA00010368A/es active IP Right Grant
- 1999-04-23 NZ NZ507455A patent/NZ507455A/en unknown
- 1999-04-23 TR TR2000/03101T patent/TR200003101T2/xx unknown
- 1999-04-23 US US09/673,793 patent/US6531458B1/en not_active Expired - Fee Related
- 1999-04-23 EA EA200001097A patent/EA002428B1/ru not_active IP Right Cessation
- 1999-04-23 BR BR9909867-9A patent/BR9909867A/pt not_active Application Discontinuation
- 1999-04-23 EE EEP200000616A patent/EE04143B1/xx not_active IP Right Cessation
- 1999-04-23 CZ CZ20003779A patent/CZ290911B6/cs not_active IP Right Cessation
- 1999-04-23 ID IDW20002368A patent/ID26650A/id unknown
- 1999-04-23 CN CNB998053805A patent/CN1165309C/zh not_active Expired - Fee Related
- 1999-04-23 KR KR1020007011789A patent/KR100590622B1/ko not_active IP Right Cessation
- 1999-04-23 WO PCT/FI1999/000331 patent/WO1999055337A1/en active IP Right Grant
- 1999-04-23 SK SK1555-2000A patent/SK284600B6/sk not_active IP Right Cessation
- 1999-04-23 EP EP99916943A patent/EP1079834B1/en not_active Expired - Lifetime
- 1999-04-23 RS YUP-640/00A patent/RS49955B/sr unknown
- 1999-04-23 PT PT99916943T patent/PT1079834E/pt unknown
- 1999-04-23 PL PL343722A patent/PL192274B1/pl not_active IP Right Cessation
- 1999-04-23 IL IL13895099A patent/IL138950A0/xx active IP Right Grant
- 1999-04-23 JP JP2000545535A patent/JP4475809B2/ja not_active Expired - Lifetime
-
2000
- 2000-10-11 IL IL138950A patent/IL138950A/en not_active IP Right Cessation
- 2000-10-12 ZA ZA200005630A patent/ZA200005630B/en unknown
- 2000-10-19 HR HR20000703A patent/HRP20000703B1/xx not_active IP Right Cessation
- 2000-10-20 NO NO20005312A patent/NO318575B1/no not_active IP Right Cessation
- 2000-11-17 BG BG104958A patent/BG64766B1/bg unknown
-
2001
- 2001-03-26 HK HK01102147A patent/HK1031998A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019204689B2 (en) | Solid dosage forms of palbociclib | |
KR100348842B1 (ko) | 염기성물질로안정화된약제학적조성물 | |
AU756422B2 (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
HU229134B1 (en) | Process of forming a compressed solid oral dosage form comprising valsartan | |
PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
KR100202154B1 (ko) | 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제 | |
KR970069038A (ko) | 시사프라이드의 즉시 방출형 ph-비의존성 고형 제제 | |
EP1035838A1 (en) | Pharmaceutical suspension tablet compositions | |
KR20010086062A (ko) | 고가용성 약물용 서방성 메트리스 시스템 | |
AU687744B2 (en) | More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent | |
KR20050043765A (ko) | 방출 제어형 메트포르민 정제 | |
NO318575B1 (no) | Stabile sammensetninger som omfatter levosimendan og alginsyre | |
JPH0140009B2 (ja) | ||
SK288240B6 (sk) | Farmaceutický prostriedok na orálne podávanie | |
JP2014012660A (ja) | ロキソプロフェン含有医薬組成物 | |
JPH10226644A (ja) | 医薬組成物 | |
JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
CS276556B6 (en) | Pharmaceutical with a controllable bio-disposal of active component | |
JPS59184126A (ja) | 2,6−ビス−ジエタノ−ルアミノ−4,8−ジピペリジノ−ピリミド〔5,4−d〕ピリミジン含有医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |